CHARACTERISTICS OF CHANGES IN THE MICROFLORA OF PERIODONTAL POCKETS AFTER COMPLEX TREATMENT OF TOBACCO-DEPENDENT PATIENTS WITH CHRONIC GENERALIZED PERIODONTIS ON THE BACKGROUND OF CHRONIC HYPERACID GASTRITIS
DOI:
https://doi.org/10.35220/2078-8916-2020-37-3-30-35Keywords:
periodontitis, periodontopathogens, gastritis, smokingAbstract
Today, inflammatory and dystrophic periodontal diseases, which develop against the background of risk factors and concomitant somatic pathology, remain an urgent unre-solved problem of modern dentistry.
The aim of the work is to characterize the changes in the microflora of periodontal pockets after complex treatment of smoking patients with chronic generalized periodontitis on the background of chronic hyperacid gastritis.
Materials and methods. 90 patients aged 25 to 44 years old were studied and divided into 3 groups: 1st – 48 pa-tients with CHGP and chronic hyperacid gastritis (CHHG) associated with Helicobacter pylori, with a smoking history of 5-7 years and the number of cigarettes smoked from 15 to 20 per day; 2nd – 22 patients with CHGP and CHHG associated with Helicobacter pylori, but without the bad habit of smoking; 3rd - control group consisted of 20 healthy individuals. Smoking patients were randomly divided into two groups depending on the chosen method of treatment: the 1st subgroup – the use of basic therapy of CHGP and developed treatment preven-tion complex – TPC (ultraphonophoresis procedures with the created gel "Apisan", and probiotic drug BioGaia ProDentis and angioprotective drug – Detralex); the 2nd subgroup – the use of basic therapy of CHGP and ultra-phonophoresis procedures with placebo. In order to as-sess the microbiocenosis of periodontal and gingival pockets, a molecular genetic study of quantitative deter-mination of periodontopathogens and qualitative deter-mination of oral Helicobacter pylori was performed.
The results of the study. The use of a treatment-and-prophylactic complex in tobacco-dependent patients and patients without a bad habit with CHGP and CHHG as-sociated with Helicobacter pylori has shown a positive quantitative and species reduction of periodontal patho-gens, as well as a reduction in the prevalence of oral Helicobacter pylori infection.
Conclusion. The results of PCR analysis after treatment allowed to establish the effectiveness of TPC in smoking patients and patients without a bad habit, with CHGP on the background of acid-dependent diseases of the stom-ach. The proposed TPC has demonstrated elimination properties against periodontopathogenic bacteria and oral Helicobacter pylori, which allows us to recommend TPC for use in the complex treatment of CHGP against the background of risk factors.
References
Подгаецкая О.Е. Этиология и патогенез хрониче-ского генерализованного пародонтита / О.Е. Подгаецкая // Буковинський медичний вісник. – 2007. – №1. – С.127.
Ільчишин М.П. Поширеність захворювань паро-донту серед тютюнозалежних осіб / М.П. Ільчишин, А.І. Фурдичко, А.Я. Бариляк // Новини стоматології. – 2018. – №4(97). – С.86-88.
Ярова С. П. Особенности распространения и те-чения воспалительно-дистрофических процессов в пародон-те на фоне заболеваний желудочно-кишечного тракта / С. П. Ярова, В. С. Алексеева // Український стоматологічний альманах. – 2014. – № 2. – С. 105-107.
Савичук Н. О. Колонізаційна резистентність по-рожнини рота / Н. О. Савичук // Український медичний ча-сопис. – 2012. – № 4. – С. 57-63.
Socransky SS. Microbial complexes in subgingival plaque / Socransky SS., Haffajee AD., Cugini MA., Smith C., Kent Jr. RL. // Journal of Clinical Periodontology. – 1998. – №25. – Р.134-144.
Данилевський Н.Ф. Заболевания пародонта / Н.Ф. Данилевський, А.В. Борисенко. – К.: Здоров’я, 2000. – 462 с.
Патент на корисну модель України №119715 МПК (2017.01) А61К36/00 Гель «Апісан» для місцевого лікування та профілактики травматичних уражень слизової оболонки порожнини рота / Кравченко Л.С. заявник і патентовласник
Одеський національний медичний університет. - №u201702228 від 10.03.2017. – 2017. – Бюл. №19.
